In vitro aerosol characterization of Staccato® Loxapine
Khe V. Dinh(Alexza Pharmaceuticals (United States)), James V. Cassella(Trevi Therapeutics (United States)), Peter D. Noymer(Alexza Pharmaceuticals (United States)), Kathleen Simis(Alexza Pharmaceuticals (United States)), Marc Glazer(Alexza Pharmaceuticals (United States)), Caitlin Devereaux(Alexza Pharmaceuticals (United States)), Corinna Choosakul(Alexza Pharmaceuticals (United States)), Qiang Chen(Alexza Pharmaceuticals (United States)), Tamara Shmidt(Alexza Pharmaceuticals (United States)), Min He(Alexza Pharmaceuticals (United States)), Dan J. Myers(Alexza Pharmaceuticals (United States))
Cited by 42
Related Papers
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
|The British Journal of Psychiatry|2011|153
The design and calibration of a startle measurement system
|Physiology & Behavior|1986|142
Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine
|Bipolar Disorders|2012|124
Opposing roles of the amygdala and dorsolateral periaqueductal gray in fear-potentiated startle
|Neuroscience & Biobehavioral Reviews|1997|108
Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study
|Journal of Investigative Dermatology Symposium Proceedings|2020|105